Systemic Medications and Their Impact on Dental Implant Osseointegration- A Review

Abstract

Dental implants are a widely accepted treatment for rehabilitating partially or completely edentulous patients. However, implant failure remains a concern, especially in individuals on long-term pharmacological therapy. Evidence suggests that systemic medications such as NSAIDs, corticosteroids, bisphosphonates, SSRIs, PPIs, chemotherapeutic agents, and antihypertensives may impair osseointegration and peri-implant tissue health by affecting bone remodelling, angiogenesis, and immune responses. This review critically analyzes the impact of these drugs on implant outcomes, underlying mechanisms, and clinical evidence, while emphasizing risk assessment and management strategies to optimize implant success in medically compromised patients.

Introduction: Dental implants have significantly advanced prosthodontic rehabilitation by providing a reliable and esthetic solution for the replacement of missing teeth. The long-term success of implants depends on osseointegration, a biological process involving the direct structural and functional connection between the implant surface and alveolar bone. Although local factors such as bone quality, implant design, and surgical technique are well established, systemic conditions—particularly medication use—are increasingly recognized for their impact on implant prognosis. Several widely prescribed systemic drugs can influence bone metabolism, healing, and vascularization, thereby affecting osseointegration. Nonsteroidal anti-inflammatory drugs (NSAIDs) may delay bone healing by inhibiting prostaglandin synthesis, while corticosteroids can suppress bone formation and contribute to osteopenia [1]. Bisphosphonates, used in managing osteoporosis and metabolic bone disorders, inhibit osteoclastic activity and may compromise bone remodelling around implants [18,19]. Selective serotonin reuptake inhibitors (SSRIs) are linked to decreased bone mineral density, whereas proton pump inhibitors (PPIs) reduce calcium absorption and impair bone turnover [32,37]. Chemotherapeutic agents can hinder osteoblast function and angiogenesis, and prolonged antihypertensive therapy may alter bone remodelling through calcium and renal metabolism [50,59]. Recognizing these pharmacological effects is essential for identifying high-risk patients, optimizing treatment planning, and improving implant success rates.

Objectives: To evaluate how commonly prescribed systemic medications affect dental implant osseointegration and to highlight their clinical implications and strategies for optimizing implant success.

Conclusions: Systemic medications can significantly influence dental implant osseointegration by affecting bone metabolism, healing, and vascularization. Awareness of these drug–implant interactions enables clinicians to identify high-risk patients, tailor treatment planning, and implement strategies to enhance implant survival and achieve predictable long-term outcomes.